Home

Disease management

Alzheimer's Disease

Read time: 4 min

Congress highlights

An age of uncertainty: controversies in the epidemiology of AD

In developed countries, AD is being diagnosed several years later than twenty years ago. But have...

Alzheimer's Disease

Read time: 4 min

Congress highlights

From education to gait: fresh insights into MCI

Education, walking speed, striatal amyloid deposition, abnormal perceptions or thoughts, and scores...

Alzheimer's Disease

Read time: 4 min

Congress highlights

Cognitive impairment, driving, and the utility of biomarkers

Even mild cognitive impairment affects driving performance. So we should think about guidelines for...

Alzheimer's Disease

Read time: 4 min

Congress highlights

Biomarkers’ best days lie ahead

Growing evidence of the predictive value of biomarkers is refining our clinical and biological...

Read time: 3 min

Congress highlights

Coming soon….Updated APA guideline on schizophrenia

Practice guidelines assimilate the evidence-base and so help support daily clinical decision-making...

Read time: 3 min

Congress highlights

Trials on trial: what do meta-analyses reveal about efficacy and bias?

Trials of drug therapy are generally double-blind, while in psychotherapy studies it is difficult...

Read time: 4 min

Congress highlights

Depression has many faces: impaired cognition an important feature

Cognitive impairment is common, even in people with remitted depression. It has major consequences...

Alzheimer's Disease

Read time: 4 min

Congress highlights

Psychiatrists urged to take greater role in dementia

Agitation, anxiety, apathy, depression, disinhibition and – to a lesser extent –...

Read time: 3 min

Congress highlights

From mobiles to mental health in treatment-resistant schizophrenia

High-tech devices can monitor activity, sleep and physiology using sensors in widespread use. And...

Read time: 4 min

Congress highlights

The complex construct of social cognition in schizophrenia

Social cognition deficits in schizophrenia have important functional implications. This was one of...

Read time: 6 min

Picking threads from the rich tapestry of 2016

A round-up from refugee mental health to cognitive training and the effects of a light-box on...

Read time: 4 min

Satellite symposium

Is there consensus about schizophrenia management? Debate!

Should the management focus of a patient newly diagnosed with schizophrenia be short- or long-term...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country